Cargando…
Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities
Population, genetic, and clinical studies demonstrated a causative and continuous, from other plasma lipoproteins independent relationship between elevated plasma lipoprotein (a) [Lp(a)] concentration and the development of cardiovascular disease (CVD), mainly those related to athe-rosclerotic CVD,...
Autor principal: | Fras, Zlatko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kare Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040869/ https://www.ncbi.nlm.nih.gov/pubmed/32011323 http://dx.doi.org/10.14744/AnatolJCardiol.2019.56068 |
Ejemplares similares
-
New European Society of Cardiology Guidelines on diabetes; prediabetes, and cardiovascular diseases - a truly strong base for the major paradigm shift in clinical practice?
por: Fras, Zlatko
Publicado: (2019) -
Therapeutic management of hyperlipoproteinemia (a)
por: Kosmas, Constantine E, et al.
Publicado: (2019) -
Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)
por: Kosmas, Constantine E., et al.
Publicado: (2023) -
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a)
por: Grützmacher, P., et al.
Publicado: (2017) -
Antiplatelet therapy in cardiovascular disease: Current status and future directions
por: Passacquale, Gabriella, et al.
Publicado: (2022)